Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11481600 | 0.93 | PDE3B (0.75) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11492872 | 0.91 | PDE3B (0.72) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10473655 | 0.89 | PDE3B (0.73) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10472691 | 0.89 | PDE3B (0.73) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10473878 | 0.88 | PDE3B (0.72) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10474164 | 0.88 | PDE3B (0.72) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11490889 | 0.88 | PDE3B (0.75) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11180094 | 0.87 | PDE3B (0.67) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL11481527 | 0.87 | PDE3B (0.67) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL10810943 | 0.87 | PDE3B (0.70) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | claimed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4376771-A | ANTI-HYPERTENSIVE AGENTS AND ANTI-THROMBOTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1983-03-15 | — | — | US | claimed |
| EP-0000113-B1 | DIHYDROPYRIDAZONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM AND DIHYDROPYRIDAZONES FOR USE IN MEDICAL TREATMENTS | BASF Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | claimed |
| EP-0000113-A1 | Dihydropyridazones, their preparation and medicines containing them and dihydropyridazones for use in medical treatments | BASF Aktiengesellschaft (DE) | 1979-01-10 | — | — | EP | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-0000113-B1 | DIHYDROPYRIDAZONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM AND DIHYDROPYRIDAZONES FOR USE IN MEDICAL TREATMENTS | BASF Aktiengesellschaft (DE) | 1981-09-16 | — | — | EP | disclosed |
| EP-0000113-A1 | Dihydropyridazones, their preparation and medicines containing them and dihydropyridazones for use in medical treatments | BASF Aktiengesellschaft (DE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE3B 84/4885PDE3A 81/4885KDM4E 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.